Response of authors to Ganju and Dias’ comments on ‘Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful’ by D. A. Parasrampuria and L. Z. Benet

Publisher： John Wiley & Sons Inc

E-ISSN： 1742-7843|117|6|367-367

ISSN： 1742-7835

Source： BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol.117, Iss.6, 2015-12, pp. : 367-367

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Response to ‘Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 studies has not been Justified and on Balance is Not Useful’ by D.A. Parasrampuria and L.Z. Benet

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 6, 2015-12 ,pp. : 365-366

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inclusion of Placebos and Blinding for Ascending Dose First‐in‐Human Studies and Other Underpowered Phase 1 Studies has not been Justified and on Balance is Not Useful

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 1, 2015-07 ,pp. : 44-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase 1, Randomized Ascending Single‐Dose Study of Antagonist Anti‐Human CD40 ASKP1240 in Healthy Subjects

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 13, Iss. 4, 2013-04 ,pp. : 1040-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 10, Iss. 7, 2012-07 ,pp. : 1303-1311

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 162, Iss. 2, 2013-07 ,pp. : 191-201

John Wiley & Sons Inc

Access to resources Recommend Favorite